Literature DB >> 26753006

Pharmacologic resistance in colorectal cancer: a review.

William A Hammond1, Abhisek Swaika1, Kabir Mody2.   

Abstract

Colorectal cancer (CRC) persists as one of the most prevalent and deadly tumor types in both men and women worldwide. This is in spite of widespread, effective measures of preventive screening, and also major advances in treatment options. Despite advances in cytotoxic and targeted therapy, resistance to chemotherapy remains one of the greatest challenges in long-term management of incurable metastatic disease and eventually contributes to death as tumors accumulate means of evading treatment. We performed a comprehensive literature search on the data available through PubMed, Medline, Scopus, and the ASCO Annual Symposium abstracts through June 2015 for the purpose of this review. We discuss the current state of knowledge of clinically relevant mechanisms of resistance to cytotoxic and targeted therapies now in use for the treatment of CRC.

Entities:  

Keywords:  colon adenocarcinoma; colon cancer; resistance

Year:  2016        PMID： 26753006      PMCID： PMC4699262          DOI： 10.1177/1758834015614530

Source DB:  PubMed          Journal:  Ther Adv Med Oncol        ISSN： 1758-8340            Impact factor:   8.168


  189 in total

Review 1.  DNA mismatch repair genes and colorectal cancer.

Authors:  J M Wheeler; W F Bodmer; N J Mortensen
Journal:  Gut       Date:  2000-07       Impact factor: 23.059

2.  The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling.

Authors:  E J Lowenstein; R J Daly; A G Batzer; W Li; B Margolis; R Lammers; A Ullrich; E Y Skolnik; D Bar-Sagi; J Schlessinger
Journal:  Cell       Date:  1992-08-07       Impact factor: 41.582

3.  The S492R EGFR ectodomain mutation is never detected in KRAS wild-type colorectal carcinoma before exposure to EGFR monoclonal antibodies.

Authors:  Claudia Esposito; Anna Maria Rachiglio; Maria Libera La Porta; Alessandra Sacco; Cristin Roma; Alessia Iannaccone; Fabiana Tatangelo; Laura Forgione; Raffaella Pasquale; Americo Barbaro; Gerardo Botti; Fortunato Ciardiello; Nicola Normanno
Journal:  Cancer Biol Ther       Date:  2013-09-23       Impact factor: 4.742

4.  ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy.

Authors:  Y Shirota; J Stoehlmacher; J Brabender; Y P Xiong; H Uetake; K D Danenberg; S Groshen; D D Tsao-Wei; P V Danenberg; H J Lenz
Journal:  J Clin Oncol       Date:  2001-12-01       Impact factor: 44.544

Review 5.  Epidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspectives.

Authors:  J P Spano; R Fagard; J-C Soria; O Rixe; D Khayat; G Milano
Journal:  Ann Oncol       Date:  2005-02       Impact factor: 32.976

6.  Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors.

Authors:  Oriol Casanovas; Daniel J Hicklin; Gabriele Bergers; Douglas Hanahan
Journal:  Cancer Cell       Date:  2005-10       Impact factor: 31.743

7.  Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance.

Authors:  Scott Kopetz; Paulo M Hoff; Jeffrey S Morris; Robert A Wolff; Cathy Eng; Katrina Y Glover; Rosie Adinin; Michael J Overman; Vincete Valero; Sijin Wen; Christopher Lieu; Shaoyu Yan; Hai T Tran; Lee M Ellis; James L Abbruzzese; John V Heymach
Journal:  J Clin Oncol       Date:  2009-12-14       Impact factor: 44.544

Review 8.  Genetic variability in CYP3A5 and its possible consequences.

Authors:  Hong-Guang Xie; Alastair J J Wood; Richard B Kim; C Michael Stein; Grant R Wilkinson
Journal:  Pharmacogenomics       Date:  2004-04       Impact factor: 2.533

Review 9.  Targeted therapy for metastatic colorectal cancer: role of aflibercept.

Authors:  Edith P Mitchell
Journal:  Clin Colorectal Cancer       Date:  2012-10-24       Impact factor: 4.481

10.  Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy.

Authors:  J M Jürgensmeier; H-J Schmoll; J D Robertson; L Brooks; M Taboada; S R Morgan; D Wilson; P M Hoff
Journal:  Br J Cancer       Date:  2013-02-28       Impact factor: 7.640
View more
  140 in total

1.  Regorafenib antagonizes BCRP-mediated multidrug resistance in colon cancer.

Authors:  Yun-Kai Zhang; Yi-Jun Wang; Zi-Ning Lei; Guan-Nan Zhang; Xiao-Yu Zhang; De-Shen Wang; Sweilem B Al-Rihani; Suneet Shukla; Suresh V Ambudkar; Amal Kaddoumi; Zhi Shi; Zhe-Sheng Chen
Journal:  Cancer Lett       Date:  2018-10-28       Impact factor: 8.679

2.  Regorafenib: lights and shadows of antiangiogenic therapies in gastric cancer.

Authors:  Caterina Vivaldi; Alfredo Falcone; Lorenzo Fornaro
Journal:  Transl Gastroenterol Hepatol       Date:  2017-02-23

Review 3.  MicroRNAs are important regulators of drug resistance in colorectal cancer.

Authors:  Yang Zhang; Jing Wang
Journal:  Biol Chem       Date:  2017-07-26       Impact factor: 3.915

4.  Engineering bacteria for cancer therapy.

Authors:  Tetsuhiro Harimoto; Tal Danino
Journal:  Emerg Top Life Sci       Date:  2019-11-11

Review 5.  The emerging role of noncoding RNAs in colorectal cancer chemoresistance.

Authors:  Ling Wei; Xingwu Wang; Liyan Lv; Yan Zheng; Nasha Zhang; Ming Yang
Journal:  Cell Oncol (Dordr)       Date:  2019-07-29       Impact factor: 6.730

6.  Sensitization of colorectal cancer to irinotecan therapy by PARP inhibitor rucaparib.

Authors:  Titto Augustine; Radhashree Maitra; Jinghang Zhang; Jay Nayak; Sanjay Goel
Journal:  Invest New Drugs       Date:  2019-01-05       Impact factor: 3.850

7.  Anti-cancer effects of chemotherapeutic agent; 17-AAG, in combined with gold nanoparticles and irradiation in human colorectal cancer cells.

Authors:  Zhino Moradi; Mahshid Mohammadian; Hassan Saberi; Meysam Ebrahimifar; Zeinab Mohammadi; Mahnaz Ebrahimpour; Zhaleh Behrouzkia
Journal:  Daru       Date:  2019-03-05       Impact factor: 3.117

8.  Improving anticancer activity towards colon cancer cells with a new p53-activating agent.

Authors:  Liliana Raimundo; Margarida Espadinha; Joana Soares; Joana B Loureiro; Marco G Alves; Maria M M Santos; Lucília Saraiva
Journal:  Br J Pharmacol       Date:  2018-09-06       Impact factor: 8.739

9.  PIK3R3 promotes chemotherapeutic sensitivity of colorectal cancer through PIK3R3/NF-kB/TP pathway.

Authors:  Sidikjan Ibrahim; Guodong Li; Fuqing Hu; Zhenlin Hou; Qianzhi Chen; Geng Li; Xuelai Luo; Junbo Hu; Yongdong Feng
Journal:  Cancer Biol Ther       Date:  2018-01-25       Impact factor: 4.742

10.  A natural flavonoid lawsonaringenin induces cell cycle arrest and apoptosis in HT-29 colorectal cancer cells by targeting multiple signalling pathways.

Authors:  Areeba Anwar; Nizam Uddin; Bina Shaheen Siddiqui; Rafat Ali Siddiqui; Sabira Begum; Muhammad Iqbal Choudhary
Journal:  Mol Biol Rep       Date:  2018-08-07       Impact factor: 2.316
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.